


Comparison of bone marrow high mitotic index metaphase fluorescence *in situ* hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia

Tuija Lundán,^{1,2,3} Vesa Juvonen,⁴ Martin C. Mueller,⁵ Satu Mustjoki,^{2,6} Taina Lakkala,⁷ Veli Kairisto,⁴ Andreas Hochhaus,⁵ Sakari Knuutila,¹ and Kimmo Porkka^{2,8}


¹Department of Pathology, Laboratory of Molecular Pathology, Haartman Institute and HUSLAB, Helsinki, Finland; ²Hematology Research Unit, Biomedicum Helsinki, Helsinki, Finland; ³Department of Clinical Genetics, University of Oulu and Oulu University Hospital, Oulu, Finland; ⁴TYKSLAB, Turku University Hospital Laboratories, Turku, Finland; ⁵III. Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany; ⁶Department of Clinical Chemistry, HUSLAB, Laboratory of Hematology, Helsinki University Central Hospital, Helsinki, Finland; ⁷Department of Medical Genetics, University of Turku, Turku, Finland and ⁸Department of Medicine, Division of Hematology, Helsinki University Central Hospital, Helsinki, Finland

Citation: Lundán T, Juvonen V, Mueller MC, Mustjoki S, Lakkala T, Kairisto V, Hochhaus A, Knuutila S, and Porkka K. Comparison of bone marrow high mitotic index metaphase fluorescence *in situ* hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia. *Haematologica* 2008 Feb; 93(2):178-185. DOI: 10.3324/haematol.11910


Supplementary Figures 1-3



Supplementary Figure 1. Relation of BM and PB BCR-ABL/GUS transcript ratios in four representative patients.



Supplementary Figure 2. Basic principle of calculating the International Scale in the present study for both PB and BM samples. MMR, major molecular response (3 log reduction from baseline); CF, conversion factor from laboratory data to the international scale.



Supplementary Figure 3. Correspondence of the International Scale to the percentage of Ph positive cells in BM as assessed by FISH.

Supplementary Table 1

Supplementary Table

Association of BM *BCR-ABL/GUS* transcript level at diagnosis to selected prognostic factors and to imatinib therapy response

BM <i>BCR-ABL/GUS</i> transcript ratio at diagnosis			
<i>Variable*</i>	<i>Low (< 0.34)</i>	<i>High (≥ 0.34)</i>	<i>p-value**</i>
Age at diagnosis (yrs)	55.1 (15; 38.2-76.5)	45.5 (16; 26-65.8)	0.16
Male / Female	10 / 6	11 / 5	0.71
Sokal score at diagnosis	0.86 (14; 0.69-1.83)	0.91 (12; 0.64-2.08)	0.84
Hasford score	871.1 (14; 326.1-2007.4)	749.2 (11; 99.7-1920.8)	0.38
Spleen size at diagnosis (cm)	3 (14; 0-10)	3 (12; 0-10)	0.89
Lactate dehydrogenase at diagnosis (U/L)	748 (4; 498-2182)	1310 (7; 1034-1583)	0.19
<u>Bone marrow counts at diagnosis</u>			
Blasts (%)	2 (14; 0-4)	2 (10; 1-5)	0.93
Basophils (%)	2 (14; 0-21)	2 (10; 0-4)	0.98
Lymphocytes	3 (14; 1-6)	3 (10; 1-6)	0.93
<u>Blood counts at diagnosis</u>			
Hemoglobin (g/L)	128 (15; 88-161)	117 (16; 76-137)	0.28
Platelet count	296 (15; 102-1629)	360 (16; 122-1175)	0.78
White blood cell count	74.6 (15; 18.4-219.7)	136.1 (16; 34.5-310.7)	0.082
Differential:			
Myelo- and metamyelocytes (%)	13 (14; 3-27)	20 (15; 9-32)	0.088
Blasts (%)	1 (15; 0-8)	1 (16; 0-8)	0.82
Eosinophils (%)	3 (15; 0-8)	2 (15; 0-7)	0.080
Neutrophils (%)	65 (15; 47-90)	65 (15; 52-85)	0.93
Lymphocytes (%)	5 (15; 1-27)	3 (16; 0-15)	0.32
Monocytes (%)	3 (15; 1-6)	2 (15; 0-6)	0.26
Basophils (%)	4 (15; 1-20)	3 (16; 0-10)	0.48
Imatinib response***			
Good	8	3	0.67
Suboptimal	3	3	
Failure	1	1	

* Continuous variables are expressed as median (number of cases; range)

** Mann-Whitney U test for continuous variables and Fisher's Exact test for categorical variables

*** Baccarani et al. Blood 2006.